Research is being done by Prevail Therapeutics in NYC. (I have the mutation and so does my boss's husband. Hopefully he will get into the study and I will try to report on the results)
From prevailtherapeutics.com/our...
Parkinson's Disease with GBA1 Mutation
We are developing a broad pipeline of gene therapies for a range of neurodegenerative diseases including Parkinson’s disease, frontotemporal dementia, Alzheimer’s disease, and ALS. The first indication for our lead program, PR001, the treatment of Parkinson’s disease with GBA1 mutation (PD-GBA), illustrates our precision medicine approach to treating neurodegenerative disease.
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that affects up to one million people in the United States and more than 7 million people worldwide. While Parkinson’s disease is a movement disorder that is most commonly characterized by resting tremor, bradykinesia, rigidity and gait difficulty, it is now known to impact other aspects of nervous system function, and patients can suffer from a range of non-motor symptoms including psychosis, dementia, and cognitive impairment. Pathologically, Parkinson’s disease is characterized by inclusions called Lewy bodies, which are found within neurons and are comprised predominantly of an aggregated protein called α-Synuclein. There are no treatments available that modify the progressive underlying disease process of Parkinson’s disease.
Gene mapping in recent years has led to the identification of dozens of causative and risk genes for Parkinson’s disease. Many of these genes are involved in lysosomal function or lysosomal trafficking, indicating that lysosome dysfunction is the common denominator that underlies Parkinson’s disease pathology.
For example, mutations in the glucocerebrosidase (GBA1) gene are now known to play an important role in Parkinson’s disease. It is estimated that seven to ten percent of Parkinson’s patients worldwide, and up to 10 percent of Parkinson’s patients in the United States carry a GBA1 mutation. GBA1 encodes the lysosomal enzyme glucocerebrosidase (GCase), which is required for the disposal and recycling of glycolipids, a type of cellular lipid component that is known to accumulate with aging. Reduced levels of GCase activity in Parkinson’s patients with GBA1 mutations may lead to accumulation of glycolipids, which is toxic and can cause inflammation, leading to lysosomal dysfunction and aggregation of α-Synuclein in cells.
We are also developing PR001 for the treatment of neuronopathic Gaucher disease. PD-GBA and Gaucher disease share the same underlying genetic mechanism, as Gaucher disease is defined by the presence of mutations in both chromosomal copies of GBA1, and we believe they represent a continuum of disease.